Current Oncology Reports

, Volume 12, Issue 6, pp 374–382 | Cite as

Should Eligible Patients with T-Cell Lymphoma Receive High-Dose Therapy and Autologous Stem Cell Transplant in the Upfront Setting?

Article

Abstract

Peripheral T-cell lymphomas (PTCL) are rare and aggressive subtypes of non-Hodgkin’s lymphoma. Compared to B cell lymphomas, the immunologic phenotype of PTCL portends a poorer prognosis, with the exception of anaplastic large cell lymphoma bearing the anaplastic lymphoma kinase protein. Patients with PTCL tend to present clinically in advanced disease states, show lower response rates to chemotherapy, and suffer from more frequent relapses and shorter remissions. The rarity of these lymphomas has made it difficult to carry out prospective, randomized trials delineating optimal treatments. Conventional and intensified chemotherapy have led to reasonable responses, but in many studies, frequent relapses. Consequently, high-dose chemotherapy and autologous stem cell transplantation (ASCT) have been actively studied in both the relapsed and upfront setting. In addition, the impact of disease status at transplantation is being investigated, though the optimal disease state at transplant is still a matter of debate, as is the timing of transplant. This article seeks to review the literature on the role of ASCT in PTCL, as well as to clarify what may be the optimal disease state in which to offer patients with PTCL autologous transplantation, if at all.

Keywords

Peripheral T-cell lymphoma Non-Hodgkin’s lymphoma Autologous stem cell transplantation Aggressive lymphoma Upfront setting Complete remission High-dose therapy 

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 1997, 89: 3909–3918.Google Scholar
  2. 2.
    Rüdiger T, Weisenburger DD, Anderson JR, et al.: Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 2002, 13:140–149.CrossRefPubMedGoogle Scholar
  3. 3.
    Swerdlow SH, Habeshaw JA, Rohatiner AZ, et al.: Caribbean T cell lymphoma/leukemia. Cancer 1984, 54:687–696.CrossRefPubMedGoogle Scholar
  4. 4.
    •• Vose JM, Armitage JO, Weisenburger D: International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008, 26:4124–4130. This study evaluates the largest cohort of 1314 cases of PTCL and NKTCL organized from 22 centers worldwide and generates conclusions regarding geographic incidence of TCL, response to chemotherapy, and impact of histologic subtype. CrossRefPubMedGoogle Scholar
  5. 5.
    Swerdlow S, Campo E, Harris N: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Edited by Swerdlow S, Campo E, Harris N. Lyon, France: International Agency for Research on Cancer; 2008:269–317.Google Scholar
  6. 6.
    Armitage JO, Vose JM, Linder J, et al.: Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin’s lymphoma. J Clin Oncol 1989, 12:1783–1790Google Scholar
  7. 7.
    Gisselbrecht C, Gaulard P, Lepage E, et al.: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998, 92:76–82.PubMedGoogle Scholar
  8. 8.
    A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987–994.Google Scholar
  9. 9.
    Ansell SM, Habermann TM, Kurtin PJ, et al.: Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma. J Clin Oncol 1997, 15:2296–2301.PubMedGoogle Scholar
  10. 10.
    Gallamini A, Stelitano C, Calvi R, et al.: Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004, 103:2474–2479.CrossRefPubMedGoogle Scholar
  11. 11.
    Iqbal J, Weisenburger DD, Greiner TC, et al.: Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 2010, 115:1026–1036.CrossRefPubMedGoogle Scholar
  12. 12.
    Escalon MP, Liu NS, Yang Y, et al.: Prognostic factors and treatment of patients with T cell NHL: the M.D. Anderson Cancer Center Experience. Cancer 2005, 103: 2091–2098.CrossRefPubMedGoogle Scholar
  13. 13.
    Coiffier B, Brousse N, Peuchmaur, et al.: Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. Ann Oncol 1990, 1:45–50.PubMedGoogle Scholar
  14. 14.
    AbouYabis A, Shenoy P, Flowers C, et al.: Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis [abstract 3452]. Presented at the American Society of Hematology Annual Meeting. December 2007.Google Scholar
  15. 15.
    Marchi E, Alinari L, Tani M, et al.: Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005, 104:2437–2444.CrossRefPubMedGoogle Scholar
  16. 16.
    Zinzani PL, Venturini F, Stefoni V, et al.: Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 2010, 21:860–863.CrossRefPubMedGoogle Scholar
  17. 17.
    Arkenau HT, Chong G, Cunningham D, et al.: Gemcitabine, cisplatin, and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 2007, 92:271–272.CrossRefPubMedGoogle Scholar
  18. 18.
    Kim JG, Sohn SK, Chae YS, et al.: CHOP plus etoposide and gemcitabine (CHOP-EG) as first line therapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006, 58:35–39.CrossRefPubMedGoogle Scholar
  19. 19.
    Philip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995, 333:1540–1545.CrossRefPubMedGoogle Scholar
  20. 20.
    Rodriguez J, Munsell M, Yazji S, et al.: Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001, 19:3766–3770.PubMedGoogle Scholar
  21. 21.
    Song KW, Mollee P, Keating A, et al.: Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003, 120:978–985.CrossRefPubMedGoogle Scholar
  22. 22.
    Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al.: Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006, 134:202–207.CrossRefPubMedGoogle Scholar
  23. 23.
    Horwitz S, Moskowitz C, Kewalramani T, et al.: Second-line therapy with ICE followed by high dose therapy and autologous stem cell transplantation for relapsed/refractory peripheral T-cell lymphomas: minimal benefit when analyzed by intent to treat [abstract 2679]. Presented at the American Society of Hematology Annual Meeting. 2005.Google Scholar
  24. 24.
    Smith S, Bolwell B, Rybicki L, et al.: Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. Bone Marrow Transplant 2007, 40:239–243.CrossRefPubMedGoogle Scholar
  25. 25.
    Blystad AK, Enblad G, Kvaloy S, et al.: High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001, 27:711–716.CrossRefPubMedGoogle Scholar
  26. 26.
    Rodriguez J, Caballero MD, Gutierrez A, et al.: High-dose chemotherapy and autologous stem cell transplantation in peripheral T cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003, 14:1768–1775.CrossRefPubMedGoogle Scholar
  27. 27.
    Jantunen E, Wiklund T, Juvonen E, et al.: Autologous stem cell transplantation in adult patients with peripheral T cell lymphoma: a nationwide survey. Bone Marrow Transplant 2004, 33:405–410.CrossRefPubMedGoogle Scholar
  28. 28.
    Rodriguez J, Conde E, Gutierrez A, et al.: The results of consolidation with autologous stem-cell transplantation in patients with peripheral T cell lymphoma in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol 2007, 18:652–657.CrossRefPubMedGoogle Scholar
  29. 29.
    Feyler S, Prince HM, Pearce R, et al.: The role of high dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007, 40:443–450.CrossRefPubMedGoogle Scholar
  30. 30.
    Yang DH, Kim WS, Kim SJ, et al.: Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transplant 2009, 15:118–125.CrossRefPubMedGoogle Scholar
  31. 31.
    Haioun C, Lepage E, Gisselbrecht C, et al.: Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol—A Group d’Etude des Lymphomes de l’Adulte study. J Clin Oncol 2000, 18:3025–3030.PubMedGoogle Scholar
  32. 32.
    Gisselbrecht C, Lepage E, Molina T, et al.: Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002, 20:2472–2479.CrossRefPubMedGoogle Scholar
  33. 33.
    •• d’Amore F, Relander T, Lauritzen G, et al.: Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T cell lymphomas (PTCLs)—overall and subtype specific results of a phase II study from the Nordic Lymphoma Group [abstract 53]. Presented at the Annual Meeting of the European Hematology Association. Berlin, Germany; 2009. This is the largest PTCL-specific prospective study of upfront ASCT in PTCL after first complete or partial remission.Google Scholar
  34. 34.
    Corradini C, Tarella C, Zallio F, et al.: Long-term follow up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006, 20:1533–1538.CrossRefPubMedGoogle Scholar
  35. 35.
    Rodriguez J, Conde E, Gutierrez A, et al.: Front-line autologous stem-cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Eur J Hematol 2007, 79:32–38.CrossRefGoogle Scholar
  36. 36.
    Mercadal S, Briones J, Xicoy B, et al.: Intensive chemotherapy (high dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008, 19:958–963.CrossRefPubMedGoogle Scholar
  37. 37.
    •• Reimer P, Rudiger T, Gessinger E, et al.: Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2008, 27:106–113. This is the second largest PTCL-specific prospective study of upfront ASCT in PTCL after first complete or partial remission. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations